Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Cerca in Study Connect
  • NCT02990611

Active, Not Recruiting

Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma and in Patients With Adjuvant Nivolumab Therapy - CA209-654

Aggiornato: 25 aprile, 2022   |   ClinicalTrials.gov

Stampa il riassunto

STAI PRENDENDO IN CONSIDERAZIONE QUESTA SPERIMENTAZIONE?
Stampa questa pagina e la guida alla sperimentazione da utilizzare come supporto nel colloquio con il tuo medico
Utilizza la guida alla sperimentazione per esplorare il processo di partecipazione a una sperimentazione clinica. Cerca di comprendere i fattori chiave da considerare prima di decidere e pensa alle domande da porre al team di professionisti sanitari che sono coinvolti nella conduzione dello studio.
Stampa questa pagina CA209-654
Scarica la guida

SELEZIONI UNA LINGUA

Dettagli della sperimentazione

  • Sesso

  • 18+

    Fascia d'età

  • Active, Not Recruiting

Opzioni di trattamento

Bracci dello studio
TERAPIA ASSEGNATA
Adjuvant Nivolumab therapy
Nivolumab monotherapy
Nivolumab/Ipilimumab combination therapy

Principali criteri di idoneità

Inclusion Criteria: - ≥ 18 years - advanced melanoma (Stage III/Stage IV) - histologically confirmed diagnosis - treatment decision for nivolumab mono- or combination therapy already taken - primary diagnosis of advanced melanoma after complete surgical tumor resection and no evidence of disease (cohort 3 only) Exclusion Criteria: - current primary diagnosis of a cancer other than advanced melanoma, that requires systemic or other treatment - previous treatment with nivolumab, for nivolumab monotherapy cohort only - current active participation in an interventional clinical trial for treatment of advanced melanoma - Patients with a current diagnosis of persisting advanced melanoma or a cancer other than advanced melanoma that requires systemic or other treatment or has not been treated curatively (as per discretion of the investigator) (cohort 3 only)

Ti consigliamo vivamente di contattare BMS per segnalare gli effetti collaterali (eventi avversi)
Qui vengono definiti gli effetti collaterali (eventi avversi) e altri eventi da segnalare
Segnala effetti collaterali (eventi avversi) o reclami sulla qualità del prodotto: informazioni mediche

Hai domande? Invia una e-mail

Hai domande?
Invia una e-mail